Explore Ascendis Pharma A/S's February 2025 financial report detailing an $18.25M share repurchase program and $9M RSU net settlement, showcasing strategic capital management.
Explore Ascendis Pharma A/S's Form 6-K for February 2025, detailing financial results for 2024 and SEC compliance. Key insights from the press release and executive signature included.
Discover key insights from Ascendis Pharma A/S's February 2025 Form 6-K, detailing warrant grants, future availability, and executive signatory information.
Discover key details from Ascendis Pharma A/S's January 2025 Form 6-K, including warrant grants, vesting schedules, and future opportunities for investors.
Explore key updates from Ascendis Pharma A/S's 6-K filing, including 2025 revenue forecasts, product launches, and strategic initiatives unveiled at the J.P. Morgan Conference.
Explore Ascendis Pharma A/S's December 2024 financial report detailing warrant exercises, capital structure changes, and share issuance impacts on shareholders.
Discover Ascendis Pharma's latest 6-K report detailing a strategic collaboration with Novo Nordisk for metabolic disease solutions, including a $100M milestone payment opportunity.